The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is Artivion (AORT) one of those stocks right now? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question. Artivion is a member of our Medical group, which includes 1051 different companies and currently sits at #4 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group. The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. Artivion is currently sporting a Zacks Rank of #1 (Strong Buy). The Zacks Consensus Estimate for AORT's full-year earnings has moved 2500% higher within the past quarter. This is a sign of improving analyst sentiment and a positive earnings outlook trend. Based on the most recent data, AORT has returned 14.4% so far this year. Meanwhile, stocks in the Medical group have gained about 0.8% on average. This means that Artivion is performing better than its sector in terms of year-to-date returns. Another Medical stock, which has outperformed the sector so far this year, is Cencora (COR). The stock has returned 13.9% year-to-date. For Cencora, the consensus EPS estimate for the current year has increased 4.3% over the past three months. The stock currently has a Zacks Rank #2 (Buy). Breaking things down more, Artivion is a member of the Medical - Instruments industry, which includes 92 individual companies and currently sits at #99 in the Zacks Industry Rank. On average, this group has gained an average of 5.4% so far this year, meaning that AORT is performing better in terms of year-to-date returns. On the other hand, Cencora belongs to the Medical Services industry. This 59-stock industry is currently ranked #67. The industry has moved +0.6% year to date. Investors with an interest in Medical stocks should continue to track Artivion and Cencora. These stocks will be looking to continue their solid performance. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Artivion, Inc. (AORT):Free Stock Analysis Report Cencora, Inc. (COR):Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research
Is Artivion (AORT) Outperforming Other Medical Stocks This Year?
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...